136 related articles for article (PubMed ID: 32449742)
1. In Vitro ELISA Test to Evaluate Rabies Vaccine Potency.
Jallet C; Tordo N
J Vis Exp; 2020 May; (159):. PubMed ID: 32449742
[TBL] [Abstract][Full Text] [Related]
2. A relevant in vitro ELISA test in alternative to the in vivo NIH test for human rabies vaccine batch release.
Gibert R; Alberti M; Poirier B; Jallet C; Tordo N; Morgeaux S
Vaccine; 2013 Dec; 31(50):6022-9. PubMed ID: 24161572
[TBL] [Abstract][Full Text] [Related]
3. An electrochemiluminescence assay for analysis of rabies virus glycoprotein content in rabies vaccines.
Smith TG; Ellison JA; Ma X; Kuzmina N; Carson WC; Rupprecht CE
Vaccine; 2013 Jul; 31(33):3333-8. PubMed ID: 23742991
[TBL] [Abstract][Full Text] [Related]
4. Development of competitive inhibition ELISA as an effective potency test to analyze human rabies vaccines and assessment of the antigenic epitope of rabies glycoprotein.
Soni D; Sahoo I; Mallya AD; Kamthe P; Sahai A; Goel SK; Kulkarni PS; Dhere RM
J Immunol Methods; 2021 May; 492():112939. PubMed ID: 33309752
[TBL] [Abstract][Full Text] [Related]
5. A time-resolved fluoroimmunoassay to assay the rabies virus glycoprotein: application for estimation of human rabies vaccine potency.
Lin G; Chen S; Zhao H; Liang J; Deng Q; Liang R; Guo X; Chen Z; Chen B; Liu T; Wu Y
Sci Rep; 2017 Aug; 7(1):7288. PubMed ID: 28779162
[TBL] [Abstract][Full Text] [Related]
6. G-protein based ELISA as a potency test for rabies vaccines.
Chabaud-Riou M; Moreno N; Guinchard F; Nicolai MC; Niogret-Siohan E; Sève N; Manin C; Guinet-Morlot F; Riou P
Biologicals; 2017 Mar; 46():124-129. PubMed ID: 28214171
[TBL] [Abstract][Full Text] [Related]
7. In vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody.
Perrin P; Morgeaux S; Sureau P
Biologicals; 1990 Oct; 18(4):321-30. PubMed ID: 2285504
[TBL] [Abstract][Full Text] [Related]
8. Biophysical virus particle specific characterization to sharpen the definition of virus stability.
Clénet D; Vinit T; Soulet D; Maillet C; Guinet-Morlot F; Saulnier A
Eur J Pharm Biopharm; 2018 Nov; 132():62-69. PubMed ID: 30118752
[TBL] [Abstract][Full Text] [Related]
9. Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA - Results of an international collaborative study.
Morgeaux S; Poirier B; Ragan CI; Wilkinson D; Arabin U; Guinet-Morlot F; Levis R; Meyer H; Riou P; Shaid S; Volokhov D; Tordo N; Chapsal JM
Vaccine; 2017 Feb; 35(6):966-971. PubMed ID: 28081969
[TBL] [Abstract][Full Text] [Related]
10. A novel in vitro ELISA for estimation of glycoprotein content in human rabies vaccines.
Aavula SM; Abhinay G; Nimmagadda SV; Maithal K
J Immunoassay Immunochem; 2017; 38(4):400-410. PubMed ID: 28436708
[TBL] [Abstract][Full Text] [Related]
11. Recombinant diabody-based immunocapture enzyme-linked immunosorbent assay for quantification of rabies virus glycoprotein.
Nimmagadda SV; Aavula SM; Biradhar N; Rao VS; Shanmugham R; Chandran D; Thirumeni N; Singanallur NB; Villuppanoor SA
Clin Vaccine Immunol; 2010 Aug; 17(8):1261-8. PubMed ID: 20573881
[TBL] [Abstract][Full Text] [Related]
12. Rabies virus glycoprotein serology ELISA for measurement of neutralizing antibodies in sera of vaccinated human subjects.
Zhao R; Yu P; Shan Y; Thirumeni N; Li M; Lv Y; Li J; Ren W; Huang L; Wei J; Sun Y; Zhu W; Sun L
Vaccine; 2019 Sep; 37(41):6060-6067. PubMed ID: 31471146
[TBL] [Abstract][Full Text] [Related]
13. A novel site-II directed glycoprotein estimation ELISA to aid rabies vaccine manufacture for veterinary and human use.
Abhinay G; Dessain S; Srikanth A; Senthilkumar RL; Vidyasagar P; Praveen A; Chandrasekhar Reddy RV; Swapna Reddy E; Rajendra L
Vaccine; 2014 Jan; 32(2):209-13. PubMed ID: 24262315
[TBL] [Abstract][Full Text] [Related]
14. An ELISA-based antigenicity test of rabies recombinant glycoprotein cannot predict its protective potency in vivo.
Volokhov DV; Fry AM; Furtak V; Jones RM; Musiychuk K; Norikane J; Green BJ; Srinivas GB; Streatfield SJ; Yusibov V
Mol Cell Probes; 2022 Jun; 63():101815. PubMed ID: 35364264
[TBL] [Abstract][Full Text] [Related]
15. A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice.
Koraka P; Bosch BJ; Cox M; Chubet R; Amerongen Gv; Lövgren-Bengtsson K; Martina BE; Roose J; Rottier PJ; Osterhaus AD
Vaccine; 2014 Aug; 32(36):4644-50. PubMed ID: 24962755
[TBL] [Abstract][Full Text] [Related]
16. A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture.
Nagarajan T; Reddy GS; Mohana Subramanian B; Rajalakshmi S; Thiagarajan D; Tordo N; Jallet C; Srinivasan VA
Biologicals; 2006 Mar; 34(1):21-7. PubMed ID: 16188454
[TBL] [Abstract][Full Text] [Related]
17. Standardization of an enzyme immunoassay for the in vitro potency assay of inactivated tissue culture rabies vaccines: determination of the rabies virus glycoprotein with polyclonal antisera.
Thraenhart O; Ramakrishnan K
J Biol Stand; 1989 Oct; 17(4):291-309. PubMed ID: 2613705
[TBL] [Abstract][Full Text] [Related]
18. Development of a relative potency test using ELISA for human rabies vaccines.
Wang Z; Sun Y; Wu X; Carroll DS; Lv W; You L; Ji Y; Shi J; Yan J; Xu G; Meng S
Biologicals; 2018 Sep; 55():59-62. PubMed ID: 29970288
[TBL] [Abstract][Full Text] [Related]
19. Preparation and diagnostic use of a novel recombinant single-chain antibody against rabies virus glycoprotein.
Yuan R; Chen X; Chen Y; Gu T; Xi H; Duan Y; Sun B; Yu X; Jiang C; Liu X; Wu C; Kong W; Wu Y
Appl Microbiol Biotechnol; 2014 Feb; 98(4):1547-55. PubMed ID: 24241896
[TBL] [Abstract][Full Text] [Related]
20. A novel ELISA for quantification of glycoprotein in human rabies vaccines using a clinically proven virus neutralizing human monoclonal antibody.
Gairola S; Gautam M; Waghmare S
Hum Vaccin Immunother; 2020 Aug; 16(8):1857-1865. PubMed ID: 31971485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
